Alerta

Application of miR-32-5p in diagnosis and treatment of fungal ulcerative colitis

Resumen de: CN121344176A

The invention discloses an application of miR-32-5p in diagnosis and treatment of fungal ulcerative colitis. The invention finds that the expression of the miR-32-5p in an ulcerative colitis model under C.aldicans pre-planting is reduced, and the colon length of a mouse and the expression of intestinal barrier related protein in an NCM460 cell can be recovered by further increasing the expression of the miR-32-5p. Based on the discovery, the miR-32-5p can be used as a miRNA marker closely related to the fungal ulcerative colitis, is applied to preparation of diagnostic products and prevention and treatment drugs for the fungal ulcerative colitis, and provides a new thought and tool for noninvasive early diagnosis and later treatment of the ulcerative colitis.

Genomics-based irritable bowel syndrome risk marker, application and early screening kit

Resumen de: CN121344178A

The invention provides an irritable bowel syndrome risk marker based on genomics. The risk marker comprises the following six pathogenic genes: CADM2, PHF2, PCLO, SHISA6, LRP1B and TANK. According to the invention, not only is the effect of the latest large-scale whole genome association research (GWAS) on the aspect of analyzing the genetic cause of the irritable bowel syndrome shown, but also five new genetic risk variation, potential unreported pathogenic genes and treatment targets of the irritable bowel syndrome are found; a new insight is provided for the cause of the irritable bowel syndrome, and a potential therapeutic intervention target is highlighted. The invention also provides an application based on the risk marker of the irritable bowel syndrome and a corresponding early screening kit.

Knowledge base construction and experience-driven self-asking mechanism combined Crohn disease postoperative bad outcome prediction method

Resumen de: CN121354908A

The invention discloses a Crohn disease postoperative bad outcome prediction method combining knowledge base construction and an experience-driven self-asking mechanism, and solves the problems of insufficient interpretability, insufficient clinical data utilization, weak generalization ability and the like of an existing prediction method. The method comprises the following steps: constructing a Crohn disease special medical knowledge base, extracting disease progress related factors from medical literatures and real medical records, and carrying out expert score weighting processing to form searchable knowledge entries; retrieving related knowledge injection context from a knowledge base based on a medical record input by a user, and generating preliminary prediction by using a large language model; structured reasoning is guided through a multi-layer prompt engine, diagnosis tasks are decomposed through the thinking chain technology, and self-check before reasoning is achieved by driving a self-asking mechanism through experience. And generating an introspection problem chain according to historical error cases, iteratively optimizing the reasoning process, and finally outputting a bad outcome prediction result and a detailed analysis report. According to the method, both traceable interpretability and prediction accuracy are considered, and reliable assistance is provided for postoperative clinical management of Crohn's disease.

Deep learning-based inflammatory bowel disease classification and interpretable diagnosis method and system

Resumen de: CN121353785A

The invention discloses an inflammatory bowel disease classification and interpretable diagnosis method and system based on deep learning, an image acquisition module acquires image frames from colonoscope videos, and an image preprocessing module rejects low-quality images with high black pixel proportion and blurred images and executes color space normalization. The qualified image is sent to a double-stage segmentation model to obtain a polyp area mask image, the mask image is used for positioning an ROI image of the polyp area, the ROI image is input into a polyp classification model constructed based on a visual Transform structure, and a hyperplasia type or adenoma type classification result is obtained. According to the method, on the premise that extra cost input is not needed, the efficiency and accuracy of polyp recognition and grading in the colonoscope image are greatly improved, manual subjective errors are reduced, and the intelligent level and clinical practicability of early intestinal cancer screening are improved.

METHOD AND SYSTEM FOR THE DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE (IBD)

Resumen de: AU2024283890A1

The invention relates to a method and kit for the diagnosis of Inflammatory Bowel Disease (IBD) in a subject. The diagnostic method is based on the detection of fecal Calprotectin and at least one further fecal biomarker selected from PGRP-S and MMP-8 in a stool sample from the subject. In a preferred embodiment, the fecal biomarkers concentration data obtained are analyzed and classified as affected by IBD or not affected by IBD by a supervised machine learning diagnosis model.

COMPOSITIONS, DEVICES, AND METHODS OF CROHN'S DISEASE SENSITIVITY TESTING

Resumen de: US20260016486A1

Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE

Resumen de: AU2024307935A1

Aspects of the disclosure relate to compositions and methods for treating one or more inflammatory bowel diseases ("IBDs"), such as ulcerative colitis ("UC") and/or Crohn's disease. Some embodiments relate to a pharmaceutical dosage form comprising a core comprising an inhibitor of a protease (e.g., a bacterial protease) and a controlled release coating applied to an exterior surface of the core. In some cases, the protease inhibitor is a gliptin or a pharmaceutically acceptable salt thereof. In some cases, the controlled release coating is configured to release the protease inhibitor in the large intestine (e.g., colon) and/or small intestine of a subject to whom the pharmaceutical dosage form is administered. Some embodiments relate to methods of treating one or more IBDs comprising delivering a therapeutically effective amount of an inhibitor of a protease (e.g., a bacterial protease) to the large intestine (e.g., colon) and/or small intestine of a subject.

Electrochemical sensor for IBD protein marker detection, preparation method and application

Resumen de: CN121324673A

The invention discloses an electrochemical sensor for IBD protein marker detection as well as a preparation method and application of the electrochemical sensor. The electrochemical sensor is composed of a semi-cured PDMS flexible substrate in which CNT is embedded, deposited gold nanoparticles and a nucleic acid sensing layer, the nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, an interleukin 8 sensor, a transforming growth factor beta1 sensor, a reference electrode and a counter electrode; the tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the interleukin 8 sensor and the transforming growth factor beta1 sensor all adopt aptamer single chains modified by signal molecule methylene blue, and correspondingly adopt nucleotide sequences shown in SEQ ID NO.1-4. Matching and excellent biocompatibility of the sensor and human tissue modulus can be improved, and accurate detection of low-concentration biomarkers and stable signal output of the sensor under the strain working condition are achieved.

Microbial composition for screening intestinal bacteria transplantation material for treating ulcerative colitis as well as screening method and application of microbial composition

Resumen de: CN121294684A

The invention relates to a microbial composition for screening an intestinal bacteria transplantation material for treating ulcerative colitis (UC) as well as a screening method and application of the microbial composition, and belongs to the technical field of screening of intestinal bacteria transplantation materials. The invention provides a microbial composition for screening an intestinal bacteria transplantation material for treating UC. The microbial composition is prepared from the following microorganisms: Escherichia coli, anaerobe przewalskii, bacteroides shavieri, ruminococcus bromide, parabacteroides faecalis and visceral odorobacter. According to the six characteristic bacteria and the relative abundance of the six characteristic bacteria constructed by the invention, an intestinal bacteria transplantation material with relatively high content of the six bacteria can be screened out, the remission rate of UC treatment can be improved to 89.5%, and intestinal barrier healing of a patient is enhanced. When the kit is used for detecting six characteristic bacteria in the intestinal bacteria transplantation material, the specificity is high, and the sensitivity is strong; and the detection process is simple, non-invasive and low in cost.

METHODS FOR REDUCING DRUG-INDUCED LIVER INJURY

Resumen de: US20260008842A1

The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.

Crohn disease focus automatic segmentation and activity evaluation system based on deep learning

Resumen de: CN121280339A

The invention discloses a Crohn disease focus automatic segmentation and activity evaluation system based on deep learning, which belongs to the field of medical artificial intelligence and comprises a data preprocessing unit, a focus automatic segmentation unit, a radiomics feature extraction unit, a feature screening and dimension reduction unit and an activity classification unit. According to the method, an nnU-Net deep learning segmentation model is combined with image omics feature extraction, multi-stage feature screening and machine learning classification technologies, so that full-process automation from CTE image preprocessing, focus automatic segmentation, feature extraction and screening to activity classification is realized. The system can efficiently and accurately segment the focus of Crohn's disease, automatically assesses the disease activity based on the screened key radiomics characteristics, significantly improves the consistency, objectivity and efficiency of diagnosis, and is suitable for clinical auxiliary diagnosis and scientific research analysis.

Application of SETD2 and NSD2 in diagnosis and treatment of aging of intestinal stem cells

Resumen de: CN121272040A

The invention discloses an application of SETD2 and NSD2 in diagnosis and treatment of aging of intestinal stem cells. Specifically, the invention relates to application of the intestinal stem cell aging marker or the detection reagent thereof, the intestinal stem cell aging marker or the detection reagent thereof is used for preparing a diagnostic reagent or a diagnostic kit, and the diagnostic reagent or the diagnostic kit is used for judging whether intestinal stem cells are aged or not. Wherein the senescence marker combination is prepared from SETD2 and NSD2 (National Solution Development 2). Meanwhile, the invention provides a detection reagent and a kit for the intestinal stem cell marker. The detection reagent or the kit can effectively judge the aging type of the intestinal stem cells, and different effective drugs are effectively used according to different types.

CD early screening marker based on plasma proteomics, application and early screening kit

Resumen de: CN121276058A

The invention provides a Crohn disease early screening marker based on plasma proteomics. The early screening marker comprises the following nine proteins: CD274, CHI 3L1, REG1B, ITGAV, PRSS8, ITGA11, GDF15, DEFA1DEFA1B and IL6. The early screening marker provided by the invention can accurately and non-invasively predict CD as long as 16 years before diagnosis, which provides an important value for early screening of CD high risk groups and formulation of intervention measures. The invention also provides application of the Crohn disease early screening marker and an early screening kit for Crohn disease prediction.

Mucous membrane healing evaluation method based on energy spectrum CT iodine quantification

Resumen de: CN121242609A

The invention discloses a mucous membrane healing evaluation method based on energy spectrum CT iodine quantification, and belongs to the field of medical image processing and clinical diagnose.The mucous membrane healing evaluation method comprises the following steps that an energy spectrum CT intestinal stage scanning image of a patient suffering from Crohn's disease is obtained, and a three-dimensional volume area of a diseased intestinal segment is delineated on an energy spectrum CT iodine substance decomposition graph; selecting a reference blood vessel area, and measuring an iodine concentration value; calculating a normalized iodine concentration value, wherein the normalized iodine concentration value is equal to a result obtained by dividing the iodine concentration value of the lesion intestinal segment by the iodine concentration value of the reference blood vessel region; and comparing the normalized iodine concentration value with a preset threshold value 0.44, if the normalized iodine concentration value is less than 0.44, determining that the mucous membrane is healed, otherwise, determining that the active inflammation is caused. According to the scheme, traditional invasive enteroscopy is replaced with energy spectrum CT image analysis, contraindications of endoscope operation, patient pain and examination blind areas are avoided, the acceptability and examination feasibility of patients are remarkably improved, and the method is particularly suitable for p

Application of DDX24 in maintaining homeostasis of intestinal vascular barrier

Resumen de: CN121249871A

The invention belongs to the technical field of molecular biology, and discloses application of DDX24 in maintaining the homeostasis of an intestinal vascular barrier. According to the present invention, the low expression of the intestinal microvascular endothelial DDX24 in the inflammatory bowel disease (IBD) is firstly found so as to construct the adult endothelial cell specific DDX24 induced knockout mouse model, the homeostasis of the intestinal vascular barrier (GVB) of the mouse is imbalanced, and the mouse suffers from spontaneous enteritis, such that the intestinal microvascular endothelial cell DDX24 is the important molecule for maintaining the intestinal homeostasis; and mechanism research finds that the intestinal microvascular endothelial cell DDX24 inhibits cell senescence to protect the GVB steady state. The research discloses an important mechanism of DDX24 for protecting GVB homeostasis by inhibiting intestinal microvascular endothelial cell senescence for the first time, and provides a strategy and basis for clinical diagnosis and treatment of IBD vascular barrier.

ORAL-GUT-BRAIN AXIS VIROME/MICROBIOME FOR PERIODONTITIS, IRRITABLE BOWEL DISEASE AND ALZHEIMER'S DISEASE DIAGNOSTICS

Resumen de: WO2026006246A1

The disclosure provides an evaluation of the virome in health and disease of the oral-gut-brain axis, in particular, periodontitis, irritable bowel disease (IBD) and Alzheimer's Disease (AD). For Alzheimer's disease, a striking feature was found via metagenomics of brain autopsy specimens - the presence of parvoviridae (comprised of erythoviruses and erythroparvoviruses) in the brains of individuals diagnosed with Alzheimer's Disease (AD) but not in brains from age-matched healthy individuals without a medical diagnosis of AD. For IBD, For Periodontitis and IBD, an analysis revealed the top 20 most abundant viral and bacterial species in saliva samples from individuals with periodontal disease or with a healthy periodontium and the top viral and bacterial species in stool samples from individuals with irritable bowel syndrome or with gastrointestinal health. Building upon these discoveries, a number of diagnostic methods and materials for AD and IBD are described herein.

MICROBIAL METABOLITES ON INTESTINAL INFLAMMATION

Resumen de: US20260000713A1

Provided herein are methods of predicting a likelihood that a subject will develop ileitis, intestinal fibrosis or colitis based on an amount of acetate or acetate-producing bacteria detected in a sample obtained from a subject. Certain genetic risk variants at TNF super-family member 15 (TNFSF15) may also be detected. Methods, systems and kits for treatment of develop ileitis, intestinal fibrosis or colitis are also provided, which include inhibitors of acetate or acetate-producing bacteria, or targeting biologic therapeutics, such as inhibitors of Tumor necrosis factor (TNF)-like cytokine 1A (TL1A).

REVERSIBLE BACTERIAL PHSE-VARIATIONS AND USES THEREOF IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS

Resumen de: WO2024176230A1

The present disclosure relates to reversible phase variations in bacteria e.g., residing in a microbiome or any environment, and uses thereof in determining a physiological and/or environmental condition or state of a subject or a media and/or or habitat. The present disclosure thus provides methods and personalized therapeutic methods and kits.

METHODS AND COMPOSITIONS FOR MODULATING STEM-LIKE T CELLS IN AUTOIMMUNE DISEASE

Resumen de: WO2025264878A1

Provided herein are methods for treating an autoimmune disease or a fibrotic disease in a subject comprising administering to the subject an effective amount of an agent to modulate the activity of a population of T-cells expressing one or more of the targets identified herein, thereby treating the autoimmune disease or fibrotic disease in the subject.

Noninvasive intestinal flora fixed-point sampling and drug release device

Resumen de: CN121196614A

The invention discloses a non-invasive intestinal flora fixed-point sampling and drug release device, and belongs to the technical field of micro-ecological diagnosis and treatment. The device comprises a shell, an internal storage bin, a medicine loading cavity and a channel switching mechanism. The shell adopts a capsule-shaped design, and an enteric coating is arranged on the surface of the shell, so that the function is started after the shell reaches a specified position of an intestinal tract. Through the internal ingenious mechanism linkage design, the device can firstly complete non-invasive fixed-point sampling of intestinal contents, and after the sampling action is completed, a drug release mechanism is automatically triggered, so that accurate drug delivery of the same part is realized. Cooperative operation of sampling and drug release in time sequence and space is achieved, and the problems of pain, disjunction of the diagnosis and treatment process, poor drug targeting and the like caused by traditional invasive operation are effectively solved. The device is flexible in structural design, has the advantages of being noninvasive, efficient, accurate in time sequence control and the like, and is suitable for integrated application of diagnosis and treatment of various digestive tract diseases such as inflammatory bowel disease management, micro-ecological regulation and the like.

METHODS FOR ASSESSING MUCOSAL HEALING IN INFLAMMATORY BOWEL DISEASE PATIENTS

Resumen de: US2025389717A1

The present disclosure provides methods for assessing mucosal healing in a patient with Crohn's Disease. The methods include detecting expression levels of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.

NOVEL MITOCHONDRIA-TARGETING COMPOUNDS

Resumen de: EP4667476A1

0001 The present disclosure relates to a technique for synthesizing with high yield a novel compound targeting mitochondria through a simple process, and the novel compound synthesized thereby. The novel compound targeting mitochondria of the present disclosure can be synthesized with high yield through a simple process and the compound thus prepared and nanoparticles containing same exhibit the therapeutic effects of targeting mitochondria, inhibiting gastric cancer, and treating inflammatory bowel disease, and systemic sclerosis and thus can be utilized for mitochondrial targeting applications, as anticancer compositions, or as therapeutic compositions for immune diseases.

C3-HNE测定

Resumen de: WO2024240709A1

The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.

METHODS FOR THE DETECTION OF CIRCULATING MICROCLOTS AND NEUTROPHIL EXTRACELLULAR TRAPS IN INFLAMMATORY CONDITIONS

Resumen de: WO2025257752A1

This invention relates to methods of detecting inflammatory disease in a subject by detecting circulating microclots, based on combined detection or co-detection of fibrin amyloid microclots and components from Neutrophil Extracellular Traps in a sample from the subject, wherein an increased presence of fibrin amyloid microclots and NETs in the sample compared to a control or reference value is indicative of inflammatory disease in the subject. The invention also relates to kits for detecting circulating microclots to be used in the methods of detecting inflammatory disease.

SIGNATURES OF RESPONSE TO LOW-DOSE INTERLEUKIN-2 (IL2) TREATMENT IN INFLAMMATORY BOWEL DISEASE

Nº publicación: WO2025259880A1 18/12/2025

Solicitante:

THE CHILDRENS MEDICAL CENTER CORP [US]
THE BRIGHAM AND WOMENS HOSPITAL INC [US]
THE CHILDREN'S MEDICAL CENTER CORPORATION,
THE BRIGHAM AND WOMEN'S HOSPITAL, INC

Resumen de: WO2025259880A1

Provided herein are materials and methods for determining responsiveness of any therapy that enhances regulatory T cell (Treg) function in the treatment of inflammatory bowel disease (IBD). The materials and methods provided herein may be used to determine low dose IL- 2 responsiveness in a subject having an inflammatory bowel disease. The materials and methods can be used to determine low dose IL- 2 responsiveness in a blood sample prior to administering a low dose IL-2 therapy.